prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, PATIENT HISTORY: Not provided. LMP: Not provided. PRE-OP DIAGNOSIS: Left breast carcinoma. POST-OP DIAGNOSIS: Same. PROCEDURE: Left segmental mastectomy needle localization, sentinel node biopsy len axilia. COMMENT: Foci of malignant clusters and giands, surrounded by retraction type spaces are Identified, and are stained for endothelial. markers (D2-40 and CD31) for a more definitive interpretation. The results will be reported in an addendum. ER, PR and Her-2/Neu were performed on the core biopsy. and are reported as positive for receptors and. negative for Her-2/Neu. Pathologic stage: Tic NO MX. ADDENDA: Addendum. Immunostain for endothellal markers (lymphatic and vascular) highlight the endothelial cells and confirms the absence of. lymphovascular space involvement by tumor. MICROSCOPIC: Utilizing formalin-fixed (8-96 hour range). paraffin embedded tissue, immunohistology is performed with the following selected. antibodies and designated antibody clone(s), directed against the following antigenic target(s), with adequate positive and negative. internal and external controis. Antibodies are optimized appropriate for fixation times. Utilizing formalin-fixed (8-96 hour range) paraffin embedded tissue, immunchistology is. performed with the following selected antibodies and designated antibody clone (s) directed. against the following antigenic target(s). with adequate positive and negative internal and. external controls. Antibodies are optimized appropriate for fixation times. ANTIBODY. CLONE. TARGET ANTIGEN. VENDOR. D2-40. D2-40. Lymphatic Endothelium. Dako. CD 31. JC7OA. endothelium. Dako. EE/shm. The following statement applies to all immunohistochemistry, insitu hybridization (ISH & FISH), molecular anatomic pathology, and. immunofluorescence testing: The testing was developed and its performance characteristics determined by the. as. required by the CLIA '88 regulations. The testing has not been cleared or approved for the specific use by the U.S. Food and Drug. Administration, but the FDA has determined such approval is not necessary for clinical use. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-. complexity clinical testing. Pursuant to the requirements of CLIA, ASR's used in this laboratory have been established and verified for. accuracy and precision. Additional information about this type of test is available upon request. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Ségmental. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.6 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 1.9 cm. TUMOR TYPE (Invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 2. Mitotic activity score: 1. Total Nottingham score: 5. Nottingham grade (1, 2, 3): 1. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 2. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pNo. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: previously performed. PROGESTERONE RECEPTORS: previously performed. HER2/NEU: zero or 1+. FINAL DIAGNOSIS: PART 1: BREAST, LEFT, 10 O'CLOCK, NEEDLE LOCALIZED SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, TWO FOCI, 1.6 CM (GROSS) AND 0.3 CM (MICROSCOPIC), NOTTINGHAM. GRADE 1 (COMBINED NOTTINGHAM SCORE 5/9: TUBULE FORMATION -2/3, NUCLEAR GRADE- 2/3,. MITOTIC ACTIVITY- 1/3) WITH LOBULAR FEATURES. B. DUCTAL CARCINOMA IN SITU IS NOT IDENTIFIED. C. MARGINS FREE, CLOSEST ANTERIOR WITHIN 0.2 CM FROM THE LARGEST TUMOR FOCUS, SECOND. CLOSEST LATERAL WITHIN 0.5 CM FROM THE SMALLER TUMOR FOCUS. D. LYMPHOVASCULAR INVASION (SEE COMMENT). E. ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA. F. DUCTAL EPITHELIAL HYPERPLASIA. G. COLUMNAR CELL CHANGES AND HYPERPLASIA WITH ASSOCIATED MICROCALCIFICATIONS. H. FIBROADENOMATOID CHANGES. I. PSEUDOANGIOMATOUS STROMAL HYPERPLASIA (PASH). J. CAPILLARY HEMANGIOMA. -. K. CAUTERY ARTIFACT. L. BIOPSY SITE CHANGES. M. PATHOLOGIC STAGE (see comment). PART 2: NEW LATERAL MARGIN, EXCISION -. A. NEGATIVE FOR TUMOR. B. FIBROADENOMATOID CHANGES. C. FIBROCYSTIC CHANGES. D. COLUMNAR CELL CHANGES. E. DUCTAL EPITHELIAL HYPERPLASIA, MILD. F. ADENOSIS. G. PSEUDOANGIOMATOUS STROMAL HYPERPLASIA (PASH). H. CAUTERY ARTIFACT. PART 3: SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 4: SENTINEL LYMPH NODE #2, LEFT AXILLA, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). COMMENT: Foci of malignant clusters and glands surrounded by retraction type spaces are identified, and are stained for endothelial. markers (D2-40 and CD31) for a more definitive interpretation. The results will be reported in an addendum. ER, PR and Her-2/Neu were performed on the core blopsy!. and are reported as positive for receptors and. negative for Her-2/Neu. Patholoaic stage: T1c NO MX. Addendum. Immunostain for endothelial markers (lymphatic and vascular) highlight the endothelial cells and confirms the absence of. lymphovascular space Involvement by tumor.

expanded version (tokens=1856) : 
 - Histological classification: Invasive Ductal Carcinoma with lobular features
- Subtype: LumA
- Necrosis: Not mentioned
- Tumor-infiltrating lymphocytes: Not mentioned
- Histological grade: Nottingham grade 1 (tubule formation-2/3, nuclear grade-2/3, mitotic activity-1/3)
- Nuclear grade: 2
- Lymphovascular invasion: Absence of lymphovascular space involvement by tumor confirmed through immunostain for endothelial markers
- Calcification: Benign zones present
- Receptor status: ER and PR positive, HER2/Neu negative
- IHC: D2-40 and CD31 immunostaining performed for a more definitive interpretation
- Ancillary testing: None mentioned except for the above-mentioned immunohistochemistry and pathologic staging

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2054) : 
 Left segmental mastectomy of the breast revealed a subtype LumA invasive ductal carcinoma with lobular features, confirmed ER/PR positive and HER2/Neu negative through immunohistochemistry. Absence of lymphovascular space involvement was reported through immunostain for endothelial markers. Nottingham grade 1 was assigned with benign calcification zones present. The pathologic stage was T1c NO MX, with no lymph node metastasis. Additional findings include atypical ductal epithelial hyperplasia, ductal epithelial hyperplasia, columnar cell changes and hyperplasia, fibroadenomatoid changes, Pseudoangiomatous stromal hyperplasia (PASH), capillary hemangioma, ca

